‘Making More Survivors’ – Our Research Strategy 2022 – 2027 sets out how, through research, we plan to significantly impact the survival rates of the poorest prognosis cancers over the next five years.

We passionately believe in the power of research to transform cancer care and the patient experience, having already delivered new treatments with our find smart, fund fast approach. Our focus on the poorest prognosis cancers means we need to urgently have impact to remove the disparity in cancer survival rates between the so called ‘good’ cancers and ‘bad’ cancers.

This strategy reflects our ambitious vision to strive for 100% survival for 100% of cancers through cutting edge patient-focused translational research at every point of the cancer journey. New diagnostics and better treatments are urgently needed. Building capacity and embedding research into the health system will increase the number of people who survive a cancer diagnosis and improve their quality of life during treatment and beyond.


Breakthrough Cancer Research is a key funder of cancer research in Ireland. For researchers wanting to stay up to date with funding calls please sign up to our research newsletter here: Click to signup

  • Funding Information

    Breakthrough Cancer research offers funding to Irish researchers — both early-career and senior leaders — who have the potential to make significant advances in improving the survival of cancer patients through research.

    Read More
  • Public-Patient Involvement

    We have established a Public Patient Involvement (PPI) panel to make sure that we continue to support research that is important for patients and their families.

    Read More


The Gerald O’Sullivan Chair in Cancer Research

Breakthrough Cancer Research in 2019 commenced funding an endowed leadership chair in translational cancer research for a 5 year period.

read more